Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has five projects at the preclinical stage. The company was incorporated in 2015 and is based in Wroclaw, Poland.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of CTX.WA is 86 and suggests 8% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation s
Buy
Sell